Literature DB >> 9793024

Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer.

G de Manzoni1, G Verlato, A Tomezzoli, A Guglielmi, G Pelosi, F Ricci, A Di Leo, C Cordiano.   

Abstract

BACKGROUND: Cell proliferation characteristics may reflect the aggressiveness of gastric tumors and their eventual prognosis. The aim of this study was to evaluate whether the proliferative activities determined by the antibody Ki-67 could be used as a prognostic predictor in patients affected by advanced gastric cancer.
METHODS: The prognostic significance of proliferative activity was investigated in 56 patients who underwent curative gastrectomy (R0) for advanced gastric cancer using the monoclonal antibody Ki-67. The patients were divided into three groups according to the Ki-67 labeling index of the tumors: < 10% (18 cases), 10-40% (21 cases) and > 40% (17 cases). The Cox regression model was used to evaluate the prognostic significance of the Ki-67 index controlling for age, gender, histology, depth of tumor invasion and node metastasis.
RESULTS: There was no significant relationship between the Ki-67 index and wall invasion (P = 0.80) or nodal status (P = 0.73). The cumulative 3-year survival rates (95% Cl) were 61.0% (35.3-79.2%) in patients with Ki-67 index < 10%, 52.4% (29.7-70.9%) with Ki-67 index 10-40% and 52.9% (27.6-73.0%) with Ki-67 index > 40% and the differences were not statistically significant (P = 0.93). Also in multivariate analysis the proliferative activity did not independently affect survival (P = 0.98). An interaction between Ki-67 index and age was found and Ki-67 index > 40% was significantly associated with a poor prognosis in patients over 68 years old (P = 0.004).
CONCLUSION: Our study indicated that the proliferative activity in gastric cancer, determined with the monoclonal antibody Ki-67, does not influence the survival except in elderly patients (> or = 68 years old).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793024     DOI: 10.1093/jjco/28.9.534

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

1.  Combined evaluation of the expression of NUCKS and Ki-67 proteins as independent prognostic factors for patients with gastric adenocarcinoma.

Authors:  Ming Yang; Xiaoxia Wang; Qi Zhao; Tianbo Liu; Guodong Yao; Wenhao Chen; Zhiwei Li; Xiaoyi Huang; Yanqiao Zhang
Journal:  Tumour Biol       Date:  2014-05-02

2.  Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis.

Authors:  Liduan Zheng; Mixia Weng; Meng Qi; Teng Qi; Ling Tong; Xiaohua Hou; Qiangsong Tong
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-15       Impact factor: 4.553

3.  Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Authors:  Dalal M Al Tamimi; Mohamed A Shawarby; Ayesha Ahmed; Ammar K Hassan; Amal A AlOdaini
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

4.  Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics.

Authors:  Nil Culhaci; Ozgul Sagol; Sedat Karademir; Huseyin Astarcioglu; Ibrahim Astarcioglu; Mujde Soyturk; Ilhan Oztop; Funda Obuz
Journal:  BMC Cancer       Date:  2005-08-08       Impact factor: 4.430

Review 5.  Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis.

Authors:  Guanying Luo; Yunzhao Hu; Zhiqiao Zhang; Peng Wang; Zhaowen Luo; Jinxin Lin; Canchang Cheng; You Yang
Journal:  Oncotarget       Date:  2017-07-25

6.  Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.

Authors:  Gyung Hyuck Ko; Se-Il Go; Won Sup Lee; Jeong-Hee Lee; Sang-Ho Jeong; Young-Joon Lee; Soon Chan Hong; Woo Song Ha
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients.

Authors:  Dan-Dan Xiong; Chu-Mei Zeng; Ling Jiang; Dian-Zhong Luo; Gang Chen
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

8.  Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.

Authors:  Christine Böger; Hans-Michael Behrens; Christoph Röcken
Journal:  J Surg Oncol       Date:  2015-12-28       Impact factor: 3.454

9.  Ki-67 labeling index as a prognostic marker in advanced stomach cancer.

Authors:  Sang Hyuk Seo; Kwang Hee Kim; Sang Hoon Oh; Yunseon Choi; Ki Jung Ahn; Ji Young Lee; Sang Min Lee; Jisun Park; Woo Gyeong Kim
Journal:  Ann Surg Treat Res       Date:  2018-12-26       Impact factor: 1.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.